It was then suggested that in cancers with defective HRR, including ovarian cancer, an increase in NAPRT expression confers a selective advantage by ensuring the maintenance of sufficient NAD+ levels, allowing for PARP activity and cellular protection from oxidative stress and DNA damage (Figure 3A) [68]. The gene discussed is PARP1; the disease is ovarian cancer.